SHANGHAI, CHINA and REDWOOD CITY, CA--(Marketwire - Jun 14, 2012) - ChinaBio® LLC and BioCentury Publications, Inc. today announced they have agreed to a collaboration that will make news about China's rapidly growing biopharma industry more readily available to a global audience. BioCentury, the internationally respected source of biopharma business intelligence, will be a gateway to articles from ChinaBio®Today, described as the most widely read source of China-focused pharmaceutical news.

Beginning today, BioCentury will feature ChinaBio®Today's "Week in Review" summary of each week's major stories at www.biocentury.com. Other major stories from ChinaBio also will be made available on BioCentury's website in their complete form.

According to ChinaBio's Shanghai research team, China is now the third-largest pharmaceutical market in the world, growing at over 20% per year. Chinese life science companies generated over $5 billion in proceeds from IPOs in 2011, and raised nearly $1 billion in venture capital and private equity funding. There were also over 60 partnering deals, many between Western and Chinese companies, with several reaching total potential deal values of over $100 million.

"China is now an integral part of any life science company's strategy, and ChinaBio® Today together with BioCentury will detail the development of this rapidly growing market," said Greg Scott, CEO and Founder of ChinaBio®. "BioCentury is globally respected for its analysis of the life sciences, and we are honored to have them share our content on China's dynamic pharma industry."

"BioCentury respects ChinaBio's efforts to provide access to China's burgeoning biopharma space via its research, conferences and publications such as ChinaBio® Today," said David Flores, President & CEO of BioCentury. "We expect our readers to find ChinaBio's coverage of news and events to be indispensable for understanding business opportunities in China."

About ChinaBio® LLCSince its founding in 2007, ChinaBio® LLC has rapidly created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped global life science companies identify over 400 licensing and acquisition opportunities in China and has helped Chinese companies raise nearly $500 million.

Consulting: ChinaBio helps global life science companies understand the Chinese market and define and execute a successful strategy in China.

About BioCentury Now in its 20th year, BioCentury Publications, Inc. provides essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, public policy specialists and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia.

BioCentury's titles include the flagship BioCentury®, the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange™ translational science partnership with Nature Publishing Group; and its BioCentury Extra™ online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence™, an online business intelligence resource. BioCentury also produces its BioCentury This Week biotech public affairs television program in partnership with the Gannett-owned WUSA9 CBS affiliate in Washington, D.C. The program is aired in Washington each Sunday as part of the WUSA9 "Sunday Morning Power Block," and distributed globally online at www.biocenturytv.com